The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

FDA Grants Fast Track Designation to Renaissance Pharma's Daretabart

Key Facts

1The US FDA granted Fast Track designation to Daretabart for the treatment of high-risk neuroblastoma (HRNB).

2The FDA cleared the Investigational New Drug (IND) application, allowing the initiation of Phase II/III SHINE clinical trials.

Renaissance Pharma, a subsidiary of Essential Pharma, has received FDA Fast Track designation for its anti-GD2 monoclonal antibody, Daretabart. The drug is specifically designed to treat high-risk neuroblastoma (HRNB), a rare and aggressive pediatric cancer. In addition to the designation, the FDA cleared the Investigational New Drug (IND) application, enabling the commencement of Phase II/III SHINE clinical trials. Previous Phase II data demonstrated a significant overall survival rate of 86.0% among patients. This regulatory milestone is intended to accelerate the development and review process for treatments addressing critical unmet medical needs. While Renaissance Pharma is a private entity, this progress significantly enhances the clinical pipeline and valuation of the Essential Pharma group.